Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice

Brown, Ariane J.; Won, John J.; Wolfisberg, Raphael; Fahnøe, Ulrik; Catanzaro, Nicholas; West, Ande; Moreira, Fernando R.; Nogueira Batista, Mariana; Ferris, Martin T.; Linnertz, Colton L.; Leist, Sarah R.; Nguyen, Cameron; De La Cruz, Gabriela; Midkiff, Bentley R.; Xia, Yongjuan; Evangelista, Mia D.; Montgomery, Stephanie A.; Billerbeck, Eva; Bukh, Jens; Scheel, Troels K.H.; Rice, Charles M.; Sheahan, Timothy P.

Published in:
Hepatology

DOI:
10.1097/HEP.0000000000000547

Publication date:
2024

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY-NC-ND

Citation for published version (APA):

Download date: 13. mar., 2024
Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice

Ariane J. Brown1 | John J. Won1 | Raphael Wolfisberg2 | Ulrik Fahnøe2 | Nicholas Catanzaro1 | Ande West1 | Fernando R. Moreira1 | Mariana Nogueira Batista3 | Martin T. Ferris4 | Colton L. Linnertz4 | Sarah R. Leist1 | Cameron Nguyen1 | Gabriela De la Cruz5 | Bentley R. Midkiff5 | Yongjuan Xia5 | Mia D. Evangelista5 | Stephanie A. Montgomery5,6 | Eva Billerbeck7 | Jens Bukh2 | Troels K.H. Scheel2,3 | Charles M. Rice3 | Timothy P. Sheahan1

1Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
2Department of Infectious Diseases, Copenhagen Hepatitis C Program (CO-HEP), Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
3Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA
4Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
5Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
6Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
7Department of Medicine and Department of Microbiology and Immunology, Division of Hepatology, Albert Einstein College of Medicine, Bronx, New York, USA

Correspondence
Timothy P. Sheahan, Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, USA.
Email: sheahan@email.unc.edu

Abstract

Background & Aims: Human genetic variation is thought to guide the outcome of HCV infection, but model systems within which to dissect these host genetic mechanisms are limited. Norway rat hepacivirus, closely related to HCV, causes chronic liver infection in rats but causes acute self-limiting hepatitis in typical strains of laboratory mice, which resolves in 2 weeks. The Collaborative Cross (CC) is a robust mouse genetics resource comprised of a panel of recombinant inbred strains, which model the complexity of the human genome and provide a system within which to understand diseases driven by complex allelic variation.

Approach & Results: We infected a panel of CC strains with Norway rat hepacivirus and identified several that failed to clear the virus after 4 weeks. Strains displayed an array of virologic phenotypes ranging from delayed clearance (CC046) to chronicity (CC071, CC080) with viremia for at least 10 months. Body

Abbreviations: CC, Collaborative Cross; ISH, in situ hybridization; MHC, major histocompatibility complex; NrHV, Norway rat hepacivirus; ORF, open reading frame; WT, wild-type.

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal’s website, http://www.hepjournal.com.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

weight loss, hepatocyte infection frequency, viral evolution, T-cell recruitment to the liver, liver inflammation, and the capacity to develop liver fibrosis varied among infected CC strains.

**Conclusions:** These models recapitulate many aspects of HCV infection in humans and demonstrate that host genetic variation affects a multitude of viruses and host phenotypes. These models can be used to better understand the molecular mechanisms that drive hepacivirus clearance and chronicity, the virus and host interactions that promote chronic disease manifestations like liver fibrosis, therapeutic and vaccine performance, and how these factors are affected by host genetic variation.

**INTRODUCTION**

HCV causes chronic infection of the liver in a majority of those infected. If untreated, chronic HCV infection can lead to the development of end-stage liver disease, including HCC and cirrhosis, and may require liver transplantation. Curative treatments, although costly, are available yet undiagnosed cases, access to treatment, reinfection, drug resistance development, and a lack of an effective vaccine have complicated efforts for the global elimination of HCV as a public health threat. In addition, it is not yet clear if the cure will prevent the subsequent development of HCC. While human genetic variation (eg, IFNL3 locus) is thought to guide both the kinetics of spontaneous clearance and chronic infection, animal model systems within which to dissect these host genetic mechanisms are not available. Thus, our understanding of how host genetic variation affects HCV pathogenesis, the development of chronicity, immunity, and vaccine efficacy is hampered by the lack of robust immune-competent small animal models.

HCV-related hepaciviruses have been discovered in multiple animal species, including horses, nonhuman primates, wild rodents, and bats. In 2014, Norway rat hepacivirus (NrHV) was discovered in rats in New York City to cause chronic liver infection. Many basic aspects of NrHV biology are shared with HCV, including hepatotropism, genome organization, dependence on the liver-specific micro-RNA, miR-122, for replication, and the use of scavenger receptor B-1 for entry. In common lab strains of mice, NrHV causes a subclinical self-limiting hepatotropic infection that is cleared in 1–2 weeks. NrHV mouse adaptation delays clearance until after 3–5 weeks, whereas transient depletion of CD4 T-cells before infection leads to persistent infection. Models of chronic hepacivirus infection in fully immune-competent mice without immune manipulation are not yet available.

The Collaborative Cross (CC) is a robust mouse genetics resource created by the systematic breeding of 8 founder strains encompassing classic inbred, disease model, and wild-derived models resulting in the generation of a panel of recombinant inbred strains, which together model the complexity of the human genome and provide a system within which to understand disease driven by complex allelic variation. The CC contains greater than 90% of the common genetic variation in mouse resources through the presence of uniformly distributed SNPs (>40 million) and indels (>4 million) across the various genomes. When applied to virology, the CC has been a powerful tool to identify better models of human disease, as shown with the Ebola virus, severe acute respiratory syndrome-associated COV (SARS-CoV), West Nile virus, SARSCoV-2, and influenza A virus, and also to map the genetic determinants responsible for complex phenotypic traits.

Here, we describe multiple CC mouse models of chronic hepacivirus pathogenesis. We show that host genetic variation affects hepacivirus chronicity, the host response to infection, hepatocyte infection frequency, liver inflammation, liver fibrosis, and viral evolution, thus recapitulating many aspects of HCV disease biology. This system can be used to better understand the host genes and molecular mechanisms that guide hepacivirus pathogenesis, liver fibrosis, and therapeutic and vaccine performance.

**METHODS**

**Recombinant virus production**

DNA from consensus clones NrHV-A, NrHV-B, and the mouse-adapted NrHV-B, carrying the T190S, V353L, F369I, and N550S mutations were linearized using *MluI* and purified using DNAclean and concentrator (Zymo). RNA was transcribed from 1 ug of
(Thermo) at -80 °C collected from each animal and stored in RNAlater collected and treated as above. Liver tissue was harvested, titrated, and stored as above. All experiments were performed using passage #1 of each strain mixed in equal amounts (1:1:1).

Mouse infection studies

All Collaborative Cross (CC) mice were obtained in 2015–2021 from the Systems Genetics Core Facility at the University of North Carolina at Chapel Hill.[23] For the initial CC-strain screen, 9–12-week-old female CC004/TauUnc, CC017/Unc, CC021/Unc, CC024/GeniUnc, CC040/TauUnc, CC044/Unc, CC045/GeniUnc, CC046/Unc, CC071/TauUnc, and CC080/TauUnc were obtained N = 8/CC strain. Age and sex-matched WT C57BL/6J mice were purchased from Jackson Labs.

Mice were anesthetized with a mixture of ketamine/xylazine and then infected through retroorbital injection of 100 µl containing 1 × 10⁵ genome equivalents (G.E.) of recombinant NrHV diluted in DPBS (Gibco) (N = 5/strain). As a negative control, 3 mice/strain were mock infected with DPBS. Mice were weighed daily for the first week of infection and then weekly thereafter. To measure virus replication in live mice, whole blood was collected by means of submandibular bleed, was allowed to clot at room temperature in snap cap tubes, centrifuged at 9600 × g for 10 minutes, and then serum was transferred to a new tube and stored at -80 °C until analysis. A complete blood count was also performed using a Vetscan HM5c automated veterinary blood analyzer using whole blood collected into EDTA tubes. At the end of week 4, animals were euthanized by terminal bleed was performed, and serum was pooled, titrated by qRT-PCR and stored in -80 °C freezer. These passage zero virus stocks were amplified through i.v. injection of new 4-week-old NRG mice (N = 10/virus strain to be amplified) with 10⁴ genomic equivalents, after which serum harboring the new passage #1 stocks was harvested, titrated, and stored as above. All experiments were performed using passage #1 of each strain mixed in equal amounts (1:1:1).

RNA isolation, qRT-PCR, and illumina deep sequencing

For reverse transcription—quantitative PCR (qRT-PCR) quantitation of viral RNA in serum, RNA was isolated from 5 µl of mouse serum using the RNA Clean & Concentrator-5 (Zymo) or High Pure Viral Nucleic Acid kit (Roche) kits. qRT-PCR was performed using 5 µl of eluted RNA, TaqMan Fast Virus 1-step Master Mix (Applied Biosystems), and primer/probes targeting NS3 primers/probe (IDT).[10] The sequence of the NrHV NS3 primers and probes were: Primer 1: AAGC GCACGCACCAATTC, Primer 2: TACATGGCATACCGG, and Probe: /56-FAM/CTACGCAGCACCAATTCC/3IABkFQ/. NrHV standard curve RNA (MEGAscript, Thermo) was produced by PCR amplification of NS3 downstream of a T7 promoter. Reactions were performed in LightCycler 480 Multiwell Plates (Roche) in a LightCycler 480 (Roche) using the following program: 50°C for 30 minutes, 95°C for 5 minutes, followed by 40 cycles of 95°C for 15 seconds, 56°C for 30 seconds, and 60°C for 45 seconds, then 40°C for 10 seconds. For qRT-PCR to quantitate NrHV RNA, interferon-stimulated gene expression, and mRNA sequencing in liver tissue, the liver tissue was homogenized in TRIzol reagent (Thermo), and RNA was isolated according to protocol. In all, 500 ng total RNA was utilized for each qRT-PCR reaction. interferon-stimulated gene MX dynamin-like GTpase 1 (Mx1, Thermo Fisher, Mm00487796_m1) expression was assessed in select samples. Relative expression of Mx1 to housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Thermo Fisher, Mm99999915_g1) was calculated by ∆∆CT method.[24] Illumina total RNA-seq was performed by the UNC High Throughput Sequencing Facility (HTSF). Stranded mRNA libraries were prepared (Kapa mRNA) and read on the Illumina HiSeq 4000 platform (single end 1x50 read length). For analysis of raw reads, sequenced reads were mapped to the mouse reference transcriptome (Ensemble; Mus musculus version 108) using Kallisto (version 0.46.0). Transcript quantification data were normalized using the TMM method in EdgeR (version 3.38.4), and differentially expressed genes (p.Adj.val < 0.05; logLC > 1.5) were identified using linear modeling with limma (version 3.52.2) using R (version 2021–2022).
Liver pathology and digital quantitation of viral RNA in liver tissue sections

To assess liver pathology, we formalin fixed, paraffin-embedded liver tissues, generated sections (~5 µm), and stained them with hematoxylin/eosin (Richard-Allen Scientific) on an Autostainer XL from Leica Biosystems. To assess liver fibrosis, sections were stained using Masson’s Trichrome (Richard-Allen Scientific). Dual Chromogenic Immunohistochemistry was accomplished using CD4 (ab183685, Abcam) and CD8 (14-0808-82, Invitrogen) antibodies on the Ventana Discovery platform (Roche). The slides were dewaxed and hydrated. Heat-induced Ag retrieval was accomplished using Ventana’s CC1 (pH 8.5). After pretreatment, slides were incubated with primary antibodies as follows: CD8 at 1:100 and CD4 1:1000, using Discovery Casein Diluent (760-219, Roche). Ready-to-use secondary antibodies Discovery OmniMap anti-Rabbit HRP (760-4311, Roche) or Discovery OmniMap anti-Rat HRP (760-4457, Roche) were used, followed by DAB or Discovery Purple (760-229, Roche) development and Hematoxylin II staining. Stained slides were dehydrated and coverslipped with Cytoseal 60 (8310-4, Thermo Scientific). A positive control was included for each run. Tissue sections were evaluated by a Board Certified Veterinary pathologist.

NrHV viral RNA was visualized in liver tissue sections by ISH using RNAscope probes (Item # V-NrHV-PP) designed by Advanced Cell Diagnostics based on the whole genome sequence of NrHV (Genebank Accession # MF113386.1). ISH on liver tissue sections was performed on a Leica Rx autostainer (Leica Biosystems) with a hematoxylin counterstain. For quantitation, slides were scanned on a Versa slide scanner (Leica Biosystems) with a 40X power objective and a Point Gray camera (8-bit image at 0.137152 microns/pixel) and imported to Definiens Architect XD 2.7 for analysis with Tissue Studio version 4.4.2. Per tissue section per animal, the total tissue area was calculated and the total numbers of cells per section was calculated using the nuclear counterstain as a guide. Similar numbers of cells were assessed in each tissue section per timepoint. NrHV-positive cells were identified by ISH positivity. The spot size threshold was 1.5 µm². Spot areas were ranked as none/low (2 µm²), low/medium (6 µm²), or medium/high (10 µm²). Resultant data was used to determine the infection frequency per tissue section.

Deep sequencing NrHV genomes

Serum from NrHV-infected mice was diluted in PBS (25 µL in 225 µL PBS), added to a 2 mL Phasemaker tube (Thermo Fisher Scientific), and mixed with 750 µL TRIzol LS Reagent (Thermo Fisher Scientific), after which 200 µL chloroform was added, shaken for 15 seconds, incubated for 3 min at room temperature, and centrifugated at 12,000 g for 15 min at 4°C. The aqueous phase was removed and mixed with 450 µL ethanol and transferred to an RNA Clean & Concentrator-5 column (Zymo Research) for downstream RNA purification and concentration. Reverse transcription (RT) was performed with Maxima H Minus Reverse Transcriptase (Thermo Fisher Scientific). Samples were pre-incubated in the presence of RNase inhibitors (Promega) at 65°C for 2 min before the addition of the RT enzyme, followed by incubation at 50°C for 2 h using 0.1 µM primer TS-O-00319 (GCTTCTGGAGCGGGCTAGATACTG). Amplification of the complete open reading frame was performed using Q5 Hot Start High-Fidelity DNA Polymerase (New England Biolabs), including high GC Enhancer, and the primer pair Reverse TS-O-00318 (CCAAGCCCCATGGCGTC CGGCACCGCTGCCCTTTTCGG) and Forward TS-O-00361 (AGGTGAAGGGGGCATCGATG) (0.5 µM each). The PCR cycling parameters were 98°C for 30 s, followed by 37 cycles of 98°C for 10 s, 65°C for 10 s and 72°C for 8 min, with a final extension at 72°C for 10 min. Amplified DNA was purified using DNA Clean & Concentrator-25 columns (Zymo Research), and libraries for deep sequencing were prepared using the NEBNext Ultra II FS DNA Library Prep Kit for Illumina (New England Biolabs). The quality of DNA libraries was validated using a 2100 Bioanalyzer Instrument (Agilent). DNA libraries were quantitated using the Qubit dsDNA High-Sensitivity Assay Kit (Thermo Fisher Scientific), and libraries were pooled in equimolar concentrations before denaturation. Pooled libraries were loaded on a MiSeq v3 150 cycle flow-cell, and sequencing was performed on a MiSeq benchtop sequencer (Illumina). Analysis was performed as described.[11,13] In short, pair-end reads were trimmed and filtered by Sickle and subsequently mapped by BWA onto the NrHV-B reference (GenBank: ON758386) using the MEM algorithm. Samtools were used to process the alignment files, and Lofreq was applied to call SNPs that were translated by SNPEffect. Multiple mutations in the same specific codons were subsequently resolved by LinkGE. Pairwise distance and dN/dS ratios were calculated from the vcf files by SNPGenie.
RESULTS

Host genetics is a determinant of acute hepacivirus clearance

Given the profound impact human genetic variation can have on HCV infection, we aimed to determine if host genetic variation would affect NrHV pathogenesis and infection kinetics in mice (Figure 1A). We infected 10 different CC mouse strains with a mixture of 2 sub-populations of mouse-derived NrHV inoculum, NrHV-A and -B along with the mouse-adapted NrHV-BSL1S at a ratio of 1:1:1 (A:B:BSL1S) (Supplemental Figure S1, http://links.lww.com/HEP/H952).[13] We utilized this mixture to give the best possible foundation for persistency, not knowing which variant would be optimal in the CC. After infection, we monitored viremia for 4 weeks which is 1–2 weeks after WT C57BL/6J [wild-type (WT)] mice typically clear. All strains of mice became infected following NrHV inoculation (Supplemental Figure S2, http://links.lww.com/HEP/H952), but most CC strains and WT had cleared the infection by week 4. In contrast, CC040, CC046, CC071, and CC080 remained viremic at week 4 (Figure 1B), and both CC071 (p = 0.02) and CC080 (p = 0.002) had significantly elevated levels of viremia. Concurrently, CC071 (p = < 0.0001) and CC080 (p = 0.001) intrahepatic viral RNA was significantly elevated over WT (Figure 1C). Gene expression of Mx1, a typical interferon-stimulated gene, was elevated in the livers of CC strains that remained viremic, a sign that sustained virus replication continued to instigate the host (Figure 1D). All together, these data demonstrate that host genetic variation influences acute hepacivirus clearance.

Host genetics is a determinant of hepacivirus chronicity

We then further characterized a subset of CC strains with sustained NrHV replication at 4 weeks. CC046, CC071, and CC080 are genetically distinct with notably different genomic architectures, including at loci likely to be important for the antiviral response such as major histocompatibility complex (MHC), T-cell activation, and type I and III interferons (Supplemental Figure S3, http://links.lww.com/HEP/H952).[25] We infected WT, CC046, CC071, and CC080 mouse strains with NrHV as done above and monitored them for 10 months (Figure 2A). Interestingly, body weight loss was only observed in CC071-infected mice and only during the first week (Supplemental Figure S4, http://links.lww.com/HEP/H952 and Supplemental Figure S5, http://links.lww.com/HEP/H952). As expected, WT cleared the virus within 3 weeks (Figure 2B). In contrast, CC046 had sustained replication during weeks 1–4 but ultimately all mice cleared the virus by week 7 (Figure 2B). Notably, the majority of CC071 mice became chronically infected with quantifiable viremia until the termination of the study at weeks 38–39 (Figure 2B). CC080 mice had a variety of virologic outcomes where some mice cleared the virus in the middle (4–7 wk) or late (8–22 wk) times, but only a minority became chronically infected (Figure 2B). During the first 2 weeks of infection, the levels of viremia in CC071 (week 1 p = 0.007, week 2 p = 0.001) and CC080 (week 1 p = 0.036, week 2 p = 0.02) were significantly higher than WT and by week 3, viremia in all 3 CC strains exceeded that in WT mice (CC046 p = 0.006, CC071 p = 0.007, CC080

![Image](http://links.lww.com/HEP/H952)

**FIGURE 1** Host genetics is a determinant of acute hepacivirus clearance. (A) Study design. Ten Collaborative Cross (CC) strains and control C57BL/6J female mice 9–13 weeks in age were infected with 1 x 10^5 genome equivalents of recombinant NrHV or negative control PBS through retroorbital injection and bled weekly to monitor viremia. Mouse numbers per strain were: C57BL/6J N = 8, CC040 N = 4, CC017 N = 4, CC021 N = 4, CC024 N = 5, CC040 N = 5, CC044 N = 5, CC045 N = 5, CC046 N = 6, CC071 N = 5, CC080 N = 4. For all strains PBS mock infected N = 3. (B) Week 4 viremia as determined by qRT-PCR of viral RNA isolated from serum. The dotted line indicates the limit of quantitation. (C) Intrahepatic viral load 4 weeks after infection by qRT-PCR using 500 ng total liver RNA. Numbers of mice per group: C57BL/6J (8 NrHV, 4 Mock), CC040 (4 NrHV, 3 mock), CC046 (6 NrHV, 3 mock), CC071 (5 infected, 3 mock), CC080 (4 infected, 3 mock). (D) Mx1 intrahepatic gene expression 4 weeks by qRT-PCR using 500 ng total RNA. Data are expressed as fold change over mock infected by ΔΔCT method. For B and D, asterisks indicate statistical significance as determined by the Kruskal-Wallis test. For C, asterisks indicate statistical significance by 2-Way ANOVA with a Dunnnett’s multiple comparison test. Abbreviations: CC, Collaborative Cross; NrHV, Norway rat hepacivirus.
While all CC strains had measurable viremia in week 5, only CC071 (\(p = 0.01\)) remained significantly elevated over WT (Figure 2C).

To assess infectivity in serum, we passively transferred serum from 10 weeks after infection to naïve WT animals and then monitored viremia over time (Supplemental Figure S6, http://links.lww.com/HEP/H952). As expected, the transfer of serum from aviremic mice (WT and CC046) did not transfer the infection to recipient animals (Supplemental Figures S6B, S6C, http://links.lww.com/HEP/H952), but the transfer of serum from viremic CC071 (Supplemental Figure S6D, http://links.lww.com/HEP/H952) and CC080 (Supplemental Figure S6E, http://links.lww.com/HEP/H952) mice resulted in an infection in recipient animals. Thus, viral RNA associated with significant viremia is infectious. Interestingly, when examining viremia per animal, chronically infected animals experienced periods of relatively consistent levels of viremia followed by drastic increases or decreases, suggesting an interplay between the virus and the host response (Supplemental Figure S7, http://links.lww.com/HEP/H952). Altogether, by varying host genetics, a spectrum of virologic outcomes was observed following NrhV infection where all WT mice cleared early (<3 wk), most CC046 mice cleared between weeks 4–7, the majority of CC071 became chronically infected, and CC080 displayed phenotypes seen in both CC046 and CC071 (Figure 2D).

Host genetics determines infection frequency and viral dynamics in the liver

To complement our virologic measures in peripheral blood, we next extended our studies to the liver.
Labeling viral genomic RNA through *in situ* hybridization (ISH) revealed a variety of phenotypes. First, clearance phenotypes observed in the periphery were similarly observed in WT and CC046, and most CC071 and some CC080 remained viral RNA ISH-positive for the duration of the study (Figure 3A). Second, the amount of viral RNA per cell varied widely, especially at 2 dpi, where the amount of viral RNA per cell was greatest in CC071 (Figure 3A). Third, the average infection frequency varied greatly among the different strains. On 2 dpi, the infection frequency for CC046 was 22%, more than 10-fold greater than other strains (Figure 3B). By 7 dpi, the infection frequency in CC071 mice had increased to similar levels, still significantly greater than both WT and CC080 mice. By 28 dpi, the infection frequency in CC071 mice had increased even further (average frequency = 38.1%) but decreased to levels seen at earlier times by the end of the study (Figure 3B). In paired tissue samples, we quantitated viral RNA by means of qRT-PCR. As seen with ISH, CC046 had significantly elevated levels of NrHV RNA at 2 dpi (p = 0.03–0.04) compared with other CC strains (Figure 3C). Like the viremia and ISH data, CC071 had elevated levels of intrahepatic viral RNA over WT and CC046 at both 28 dpi and 272 dpi. Altogether, the intrahepatic virologic data were concordant with that observed in the periphery but also revealed new insights into the impact of host genetic variation on infection frequency and replication dynamics.

**Immune dysregulation is associated with chronic hepacivirus infection**

Given the disparate outcomes we had observed thus far, we next aimed to determine if host genetics differentially affected immune responses. First, we performed a completed blood count on longitudinal peripheral blood samples from the studies described above. The numbers of total lymphocytes were largely unaffected over time, comparing infected and strain-matched mock mice (Supplemental Figure S8A and B, http://links.lww.com/HEP/H952). In contrast, neutrophils were significantly and consistently elevated in NrHV-infected CC071 compared with strain-matched mock mice in weeks 1 and 2 (Supplemental Figures S8C and D, http://links.lww.com/HEP/H952). We hypothesize that innate immune cells like neutrophils may be responding in earnest as an attempt to compensate for inadequate innate or adaptive immune responses in CC071 mice. To better understand intrahepatic responses, we labeled liver tissue sections for CD4 and CD8 Ags since CD4 and CD8 T-cells were previously shown to be important for clearance in WT mice.[12] On 2 dpi, clusters of CD4+ and CD8+ cells were observed in the parenchyma and on portal tracts in WT mice, who most rapidly clear the virus, whereas the labeling pattern remained unchanged from mock for all infected CC strains (Figure 4). By 7 dpi, periportal CD4+ and CD8+ cells were prominent in WT, CC046, and CC071 mice, yet the staining pattern for CC080 remained like that in the uninfected mice. By 28 dpi, clusters of CD4+ and CD8+ cells in periportal and parenchymal space were readily apparent in all infected CC strains but were diminished from the previous time point in WT mice. By 39 weeks after infection, staining in WT mice was unremarkable, but clusters of CD4+ and CD8+ cells around portal tracts remained in all chronically infected CC strains and even in CC046 that had cleared after week 7.

**Dysregulation of the transcriptome in strains susceptible to prolonged infection**

To determine if early defects in the host response were associated with chronic infection, we analyzed the transcriptional responses (Figure 5) in the liver of WT and CC mouse strains on 7 dpi when significant virologic and immunologic differences were observed. Importantly, using principal component analysis (PCA), we confirmed that the global responses among mock and infected groups differed and related samples clustered together (Figure 5A). The numbers of significantly regulated genes varied with host genetics, with CC071 regulating more genes than all other strains (Figure 5B). Pathway analysis of significantly regulated genes (>1.5 Log2 fold change over mock, p < 0.05) revealed the differential regulation of canonical pathways associated with innate and adaptive immunity among WT and CC strains (Figure 5C). When focusing on select canonical pathways, including pathogen-induced cytokine storm signaling, LXR/IL-1 mediated inhibition of RXR function, Th1 signaling, and LXR/RXR activation (Figure 5D), the gene expression patterns for CC071 were different compared with WT and other CC strains. Compared with other strains, CC071 animals lacked induction of innate immune (eg, Tlr1, 6, 7, and 13), chemokine (eg, Ccl6, Cxcl1, Cxcl10), adaptive immune (eg, Cd247, Cd3), and Il-1/infammasome (eg, Il1b, Il1m, IL18rap, NLRP3, etc.) related genes. Coupled with the CD4/CD8 + cell labeling data above, collectively these data show that CC strains with prolonged and chronic infection are dysregulated in key innate and adaptive immune pathways compared with WT mice, which most rapidly clear the virus.

**Chronic infection drives continual viral evolution**

To determine if viral evolutionary patterns varied with host genetics, we deep sequenced the complete viral open reading frame in longitudinal serum samples
from select mice that either cleared the virus or developed a chronic infection (Supplemental Figure S9, http://links.lww.com/HEP/H952). Virus populations from chronically infected animals (CC071 #41, 43, 46; CC080 #58, 63) evolved over time, as evidenced by the continued branching and increased branch length in the dendrogram (Supplemental Figure S10A, http://links.lww.com/HEP/H952). In contrast, virus populations from CC046 that cleared the virus the earliest among CC strains evolved the least (Supplemental Figure S10A, http://links.lww.com/HEP/H952). Proteins/regions of the genome under positive selection accumulate non-synonymous changes at increased frequency compared with synonymous changes. We therefore compared the non-synonymous and synonymous changes (dN/dS) across the viral open reading frame. Regardless of the host genetic background and unlike other portions of the genome, the dN/dS ratio for structural proteins E1 and E2, as well as p7 was increased at all times, suggestive of positive selection (Supplemental Figure S10B, http://links.lww.com/HEP/H952).

We next analyzed the specific mutational patterns over time per mouse (Figure 6). Virus circulating in
CC071 (Figure 6A) mice generally had more amino acid consensus changes compared with CC080 (Figure 6B) or CC0046 (Figure 6C) mice at similar times after infection. This was significantly different at late times of infection (Figure 6D). In all 3 CC mouse strains, the mouse-adapted NrHV-B SLIS variant was rapidly selected for, likely due to its mutations T190S, V353L, F369I, and N550S, which adapt the virus to WT B6 mice. Several mutations residing in an MHC-I epitope conserved between mice and rats (T184A, S191F, V196A) were observed in viral genomes from all CC strains. In addition, either A698V or C715S appeared to be selected in p7 but rarely together. Disruption of the E2 glycosylation sites, N476 or N550, was previously linked to mouse adaptation. Here, N550S reverted in 2 of 3 chronically infected CC071 mice concomitantly with the disruption of another predicted glycosylation site at residues 504–506. One CC071 mouse also selected N437D, thus suggesting a link between disruption of any of the 4 predicted E2 glycosylation sites and mouse adaptation of NrHV. Further, unique changes were observed in CC071 (R984H in NS3) and CC080 (P1446S/L), the latter of which was linked to persistence. Thus, viral evolution, clearance, and chronicity were linked to host genetics.

The pathologic hallmarks of chronic liver infection vary with time and host genetics

To determine the pathological consequences of acute and chronic NrHV infection, we evaluated hematoxylin and eosin-stained liver tissue sections. The hepatic architecture did not vary among mock-infected WT, CC046, CC071, and CC080 mice (Figure 7). For WT mice, the kinetics of liver pathology largely mirrored that of virus replication. On 2 dpi, randomly distributed foci of inflammatory cells associated with single cell necrosis of hepatocytes were noted but by 7 dpi, inflammation was notably increased with moderate lymphocytic inflammation predominantly focused on portal triads along with focal, random small clusters of inflammatory cells in the parenchyma all of which was largely resolved by 28 dpi (Figure 7 and Supplemental Figure S11, http://links.lww.com/HEP/H952). In infected CC046, a mild lymphocytic periportal inflammation was noted at 7 dpi, which became moderate by 28 dpi and persisted although more mildly to the end of the study, 8 months after mice had cleared the virus (Figure 7 and Supplemental Figure S12, http://links.lww.com/HEP/H952). Although liver tissue sections from CC071 mice were unremarkable on 2 dpi, by 7 dpi, moderate periportal inflammation was observed in infected CC071 mice with increased lymphocytes in circulation (Figure 7 and Supplemental Figure S13, http://links.lww.com/HEP/H952). By 28 dpi, periportal and intraparenchymal inflammation was noted, and hepatic nuclear inclusions (Supplemental Figure S13 Inset, http://links.lww.com/HEP/H952), known to be associated with liver diseases such as HCC and NAFLD, were observed. Unlike WT and CC046, which clear infection early, by the end of the study, moderate periportal inflammation remained in infected CC071 mice. Like CC071, at 2 dpi, liver sections from CC080 infected mice were unremarkable (Figure 7 and Supplemental Figure S14, http://links.lww.com/HEP/H952). Over time, periportal inflammation and foci of intraparenchymal inflammation increased in frequency and severity, which by the end of the study was like that in CC071. Lastly, we performed Masson’s Trichrome stain on liver tissue sections from the end of the study (ie, 272 d after infection) to determine if the chronic infection and inflammation were associated with liver fibrosis (Figure 8). Remarkably, early bridging fibrosis was observed in chronically infected CC071 mice but not in chronically infected CC080 mice. While we have not mapped the causal genetic loci, these data suggest that genetic variation can guide disparate pathogenic outcomes.
DISCUSSION

Here we describe new CC mouse models of chronic hepatic virus infection that recapitulate multiple aspects of human HCV infection, including high titer viremia and replication in the liver, persistent infection with virus evolution over time, chronic liver inflammation, and liver fibrosis (Supplemental Figure S15, http://links.lww.com/HEP/H952).\cite{30,31} Aside from providing new models for the mechanistic study of acute and chronic infection,
FIGURE 6  Chronic infection drives continual viral evolution. Consensus amino acid changes observed in the NrHV ORF and frequency in virus populations for (A) CC071 animals that clear (#42, 44, 47) and become chronically infected (#41, 43, 46), (B) CC080 animals that clear (#57, 60, 61, 62) and become chronically infected (#58 and 63) and (C) CC046 animals that clear (#28, 29, 30). The heat map color intensity indicates mutation frequencies (%). Amino acid changes were included in the heat map if the position was changed at a frequency > 50% in at least 1 sample per mouse line. Mouse adaptive mutations present in the inoculum (T190S, V353L, F369I, and N550S) are highlighted in hot pink. Changes shared by more than 1 CC strain are in bold. (D) The number of amino acid consensus changes over time. Only changes occurring at a frequency of > 50% were included in the analysis. Each symbol represents the number of coding changes in virus populations from a single mouse. Asterisks indicate statistical significance by 2-way ANOVA with Sidak’s multiple comparison test. ****p < 0.0001, *p = 0.0107.

Abbreviations: CC, Collaborative Cross; NrHV, Norway rat hepacivirus; ORF, open reading frame.
pathogenesis, immunity, and vaccination, these models should provide insights into how host genetics affects acute and chronic infection at an unprecedented resolution. Susceptibility alleles for multiple pathogens have been successfully identified using the CC mouse strains, and mapping these for NrHV will be an important future direction. Although we here demonstrate that host genetic variation can have profound effects on the virologic and pathologic outcomes, with the current suite of data, it is not possible to disentangle the genetics mediating persistent infection and that which shape the immune response and pathogenesis.

Hepacivirus and hepatocyte interactions guide the trajectory of infection, likely involving but not limited to the interplay of viral innate immune antagonists, antiviral innate immune sensors, innate (eg, KCs) and adaptive immune cells (eg, T-cells), cytokines and chemokines, hepatocyte turnover, and host genetic variation (eg, IFNL3 SNPs). Here, we describe 3 genetically distinct mouse strains with a multitude of different hepacivirus infection phenotypes and disease trajectories. Interestingly, CC071 mice also have increased susceptibility to classical flaviviruses such as Zika virus (ZIKV), Powassan virus, and West Nile virus but not to the bunyavirus Rift Valley fever virus, indicating that this strain is particularly sensitive to Flaviviridae infection. JAK/STAT signaling, a key component of the interferon response, appears to function normally in CC071 as interferon treatment of MEFs from CC071 or WT results in similar levels of STAT1 phosphorylation, suggesting that defects in JAK/STAT signaling are not driving increased flavivirus

**FIGURE 7** The pathologic hallmarks of chronic liver infection vary with time and host genetics. Liver tissue sections from mock or NrHV-infected WT, CC046, CC071, and CC080 mice at 2, 7, 28, and 272 dpi were stained with hematoxylin and eosin. Hallmark features of normal liver architecture, including portal vein, bile duct, hepatic artery, central vein, and hepatocytes, are noted in each mock panel. Abbreviations: CC, Collaborative Cross; WT, wild-type; NrHV, Norway rat hepacivirus.
Neither CC046 nor CC071 appears to have a broad immune deficiency as they are not more susceptible to *Salmonella* Typhimurium infection than WT mice (ie, 129, 129S2/SvPasCrl).

There is a dearth of small animal models of chronic hepacivirus infection within which to study the virus and host factors that contribute to pathogenesis, mechanisms of viral evolution, and evasion of adaptive immunity. Sophisticated transgenic mice, human liver chimeric mice, and even mice reconstituted with both human liver and immune cells have been employed to study HCV infection, but species incompatibility complicates the modeling of immunity and chronicity. These models have the power to provide basic insights into hepacivirus biology, hepatocyte biology, innate and adaptive immunity, and mammalian genetics, as well as new immunocompetent systems within which to study hepacivirus therapeutic efficacy and vaccine performance. Thus, these and future studies should be of broad interest to the field of infectious disease biology, hepatology, and immunology.

**FIGURE 8** Liver fibrosis is associated with chronic liver infection. Liver tissue sections from mock or NrHV-infected WT, CC046, CC071, and CC080 mice at 272 dpi were stained with Masson’s Trichrome, which stains collagen blue. Inflammatory cells and early bridging fibrosis are noted. Abbreviations: CC, Collaborative Cross; NrHV, Norway rat hepacivirus; WT, wild-type.

Neither CC046 nor CC071 appears to have a broad immune deficiency as they are not more susceptible to *Salmonella* Typhimurium infection than WT mice (ie, 129, 129S2/SvPasCrl).

![Liver tissue sections from mock or NrHV-infected WT, CC046, CC071, and CC080 mice at 272 dpi were stained with Masson’s Trichrome, which stains collagen blue. Inflammatory cells and early bridging fibrosis are noted.](https://example.com/liver_fibrosis.png)

E1 and E2, presumably the main targets of the neutralizing antibody response. The MHC and T-cell–related genetic loci of WT, CC046, CC071, and CC080 are different, suggesting the potential for differential adaptive immune responses. It is likely that acute resolving and chronic infection are complex processes involving infected cell intrinsic factors and innate and adaptive immunity. Genetic differences in all these elements could in principle determine the differential outcomes observed between strains. Unfortunately, MHC haplotypes in CC strains remain largely unknown unlike common WT strains of mice.

In summary, we provide new small animal models of chronic hepacivirus infection, evidence that host genetic variation can profoundly affect the outcome of infection and a model genetic system within which to map the genetic loci guiding virus clearance and chronicity. These models have the power to provide basic insights into hepacivirus biology, hepatocyte biology, innate and adaptive immunity, and mammalian genetics, as well as new immunocompetent systems within which to study hepacivirus therapeutic efficacy and vaccine performance. Thus, these and future studies should be of broad interest to the field of infectious disease biology, hepatology, and immunology.

**AUTHOR CONTRIBUTIONS** Timothy P. Sheahan, Martin T. Ferris, Charles M. Rice, Jens Bukh, and Troels K.H. Scheel designed the studies. Ariane J. Brown, John J. Won, Raphael Wolfsberg, Ulrik Fahnøe, Nicholas Catanzaro, Ande West, Fernando R. Moreira, Martin T. Ferris, Colton L. Linnertz, Sarah R. Leist, Cameron Nguyen, Gabriela De la Cruz, Bentley R. Midkiff, Yongjuan Xia, Stephanie A. Montgomery, and Timothy P. Sheahan performed the studies. Eva Billerbeck, Mariana Nogueira Batista, and Charles M. Rice provided recombinant NrHV for these studies. Timothy P. Sheahan, Raphael Wolfsberg, Ulrik Fahnøe, Eva Billerbeck, Stephanie A. Montgomery, Troels K.H. Scheel, Jens Bukh, and Charles M. Rice wrote and edited the manuscript. All authors read and approved this manuscript.

**ACKNOWLEDGMENTS** The authors thank the technical support from the UNC High Throughput Sequencing Facility. This facility is supported by the University Cancer Research Fund, Comprehensive Cancer Center Core Support grant (P30-CA016086), and UNC Center for Mental Health and Susceptibility grant (P30-ES010126). They also thank Louise B. Christensen (Department of Clinical Microbiology, University of Copenhagen) for laboratory assistance and the Department of Clinical Microbiology, Hvidovre Hospital, for access to Illumina miSeq equipment. Collaborative Cross (CC) mice were obtained from 2017 to 2021 from the Systems Genetics Core
Funding Information
This work was funded by R01 grant from the National Institute of Allergy and Infectious Disease (NIAID, AI131688 to Charles M. Rice), a U19 grant from NIAID (U19AI100825 to Ralph Baric and Mark Heise), the Independent Research Fund Denmark (1030-00426 to Troels K.H. Scheel), Advanced Grant 4004-00598 to Jens Bukh), the Danish Cancer Society (R204-A12639 to Jens Bukh and Troels K.H. Scheel), the Novo Nordisk Foundation (Distinguished Investigator Grant NNF19OC0054518 and Tandem NNF19OC005462 to Jens Bukh), and the European Research Council (Starting Grant 802899 to Troels K. H. Scheel). Raphael Wolfisberg was supported by an Early Postdoc Mobility Fellowship (P2BE3P_178527) and a Postdoc Mobility Fellowship (P400PB-183952) from the Swiss National Science Foundation.

Conlicts of Interest
Timothy P. Sheahan received grants from GlaxoSmithKline, Regeneron, and Viiv Healthcare. The remaining authors have no conlicts to report.

ORCID
Timothy P. Sheahan https://orcid.org/0000-0001-9181-2183

References